BiotechTubeBiotechTube
Home/Pipeline/ZL-1503

ZL-1503

Atopic Dermatitis

Phase (Early Clinical)Progressing into clinic

Key Facts

Indication
Atopic Dermatitis
Phase
Phase (Early Clinical)
Status
Progressing into clinic
Company
Zai Lab

About Zai Lab

Founded in 2014 by Dr. Samantha Du, Zai Lab has grown into a leading global biopharma with a dual headquarters in China and the U.S. The company combines in-licensed assets with strategic partnerships and internal R&D to build a robust pipeline, with eight products already on the market in China. Its mission is to bridge gaps in global health by advancing breakthrough therapies for patients with significant unmet medical needs.

View full company profile

Therapeutic Areas

OncologyImmunologyNeuroscienceInfectious Disease

Other Atopic Dermatitis Drugs

DrugCompanyPhase
LebrikizumabEli LillyPhase 3
DupixentSanofiCommercial
ASP2408Astellas PharmaPhase 2
KW-6356Kyowa KirinPhase 2
KHK4083Kyowa KirinPhase 2
Opzelura (ruxolitinib cream)Ono PharmaceuticalApproved
ONO-7913Ono PharmaceuticalPhase 2
KT-474Kymera TherapeuticsPhase 2
GRC 27864Glenmark PharmaceuticalsPhase 2
ARQ-234Arcutis BiotherapeuticsPreclinical/Phase 1
STAR-0310BioCryst PharmaceuticalsPhase 1
RezpegaldesleukinNektar TherapeuticsPhase 2b